FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1534622034> ?p ?o ?g. }

• W1534622034 endingPage "198" @default.
• W1534622034 startingPage "191" @default.
• W1534622034 abstract "Around 20% of Hodgkin lymphoma (HL) patients are refractory to first-line therapy with ABVD (adriamycin-bleomycin-vinblastine-dacarbazine) or relapse after complete remission. Salvage regimens frequently have delayed courses or require dose-reduction because of haemotoxicity. We evaluated the IVOx (ifosfamide-etoposide-oxaliplatin) salvage regimen in terms of response rate, toxicity and stem-cell mobilization. Thirty-four patients with relapsed/refractory HL after anthracycline-containing chemotherapy prospectively received IVOx, consisting of ifosfamide (1500 mg/m(2) days 1-3), etoposide (150 mg/m(2) days 1-3) and oxaliplatin (130 mg/m(2) day 1). Patients <65 years old received high-dose therapy followed by autologous stem-cell transplantation (HDT-ASCT). Response was assessed by computed and positron-emission tomographies. Overall and complete response rates were 76% and 32%, respectively, after 2 cycles. Three episodes of febrile neutropenia occurred, and three patients required dose-reductions. Twenty-six patients underwent HDT-ASCT. With median follow-up at 5 years, the 5-year overall and event-free survival rates were 74% and 63%, respectively. IVOx is a well-tolerated outpatient regimen for relapsed HL, that does not hamper stem-cell mobilization, achieves good response rates and compares favourably with previously published salvage regimens." @default.
• W1534622034 created "2016-06-24" @default.
• W1534622034 creator A5021110927 @default.
• W1534622034 creator A5033073385 @default.
• W1534622034 creator A5052452447 @default.
• W1534622034 creator A5056514957 @default.
• W1534622034 creator A5060735815 @default.
• W1534622034 creator A5069282152 @default.
• W1534622034 creator A5073689790 @default.
• W1534622034 creator A5079362353 @default.
• W1534622034 creator A5085598075 @default.
• W1534622034 creator A5089493611 @default.
• W1534622034 date "2011-03-08" @default.
• W1534622034 modified "2023-10-17" @default.
• W1534622034 title "Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients" @default.
• W1534622034 cites W1901841160 @default.
• W1534622034 cites W1912693401 @default.
• W1534622034 cites W1954043953 @default.
• W1534622034 cites W1975956332 @default.
• W1534622034 cites W1978420334 @default.
• W1534622034 cites W1987792231 @default.
• W1534622034 cites W2004678634 @default.
• W1534622034 cites W2021345147 @default.
• W1534622034 cites W2028850285 @default.
• W1534622034 cites W2034218339 @default.
• W1534622034 cites W2049074090 @default.
• W1534622034 cites W2071239138 @default.
• W1534622034 cites W2071319199 @default.
• W1534622034 cites W2076334524 @default.
• W1534622034 cites W2081214099 @default.
• W1534622034 cites W2092230771 @default.
• W1534622034 cites W2094603195 @default.
• W1534622034 cites W2101623805 @default.
• W1534622034 cites W2103699612 @default.
• W1534622034 cites W2108618573 @default.
• W1534622034 cites W2112001172 @default.
• W1534622034 cites W2116838243 @default.
• W1534622034 cites W2121602104 @default.
• W1534622034 cites W2122654415 @default.
• W1534622034 cites W2128655114 @default.
• W1534622034 cites W2133201432 @default.
• W1534622034 cites W2136629418 @default.
• W1534622034 cites W2136962826 @default.
• W1534622034 cites W2140104756 @default.
• W1534622034 cites W2140402067 @default.
• W1534622034 cites W2141082026 @default.
• W1534622034 cites W2142271514 @default.
• W1534622034 cites W2142867377 @default.
• W1534622034 cites W2143878253 @default.
• W1534622034 cites W2145010435 @default.
• W1534622034 cites W2157717016 @default.
• W1534622034 cites W2158036326 @default.
• W1534622034 cites W2158380419 @default.
• W1534622034 cites W2161573782 @default.
• W1534622034 cites W2165308914 @default.
• W1534622034 cites W4249283733 @default.
• W1534622034 cites W4302388935 @default.
• W1534622034 doi "https://doi.org/10.1111/j.1365-2141.2011.08594.x" @default.
• W1534622034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21385169" @default.
• W1534622034 hasPublicationYear "2011" @default.
• W1534622034 type Work @default.
• W1534622034 sameAs 1534622034 @default.
• W1534622034 citedByCount "21" @default.
• W1534622034 countsByYear W15346220342012 @default.
• W1534622034 countsByYear W15346220342013 @default.
• W1534622034 countsByYear W15346220342014 @default.
• W1534622034 countsByYear W15346220342015 @default.
• W1534622034 countsByYear W15346220342016 @default.
• W1534622034 countsByYear W15346220342017 @default.
• W1534622034 countsByYear W15346220342020 @default.
• W1534622034 countsByYear W15346220342022 @default.
• W1534622034 crossrefType "journal-article" @default.
• W1534622034 hasAuthorship W1534622034A5021110927 @default.
• W1534622034 hasAuthorship W1534622034A5033073385 @default.
• W1534622034 hasAuthorship W1534622034A5052452447 @default.
• W1534622034 hasAuthorship W1534622034A5056514957 @default.
• W1534622034 hasAuthorship W1534622034A5060735815 @default.
• W1534622034 hasAuthorship W1534622034A5069282152 @default.
• W1534622034 hasAuthorship W1534622034A5073689790 @default.
• W1534622034 hasAuthorship W1534622034A5079362353 @default.
• W1534622034 hasAuthorship W1534622034A5085598075 @default.
• W1534622034 hasAuthorship W1534622034A5089493611 @default.
• W1534622034 hasConcept C126322002 @default.
• W1534622034 hasConcept C141071460 @default.
• W1534622034 hasConcept C143998085 @default.
• W1534622034 hasConcept C2776305933 @default.
• W1534622034 hasConcept C2776694085 @default.
• W1534622034 hasConcept C2776755627 @default.
• W1534622034 hasConcept C2777063308 @default.
• W1534622034 hasConcept C2777506904 @default.
• W1534622034 hasConcept C2778119113 @default.
• W1534622034 hasConcept C2778336483 @default.
• W1534622034 hasConcept C2778850193 @default.
• W1534622034 hasConcept C2779050716 @default.
• W1534622034 hasConcept C2779429289 @default.
• W1534622034 hasConcept C2780775027 @default.
• W1534622034 hasConcept C2780964509 @default.
• W1534622034 hasConcept C2781413609 @default.

• next